China plans to extend import VAT breaks on cancer and rare disease drugs until the end of 2027

China's decision to extend import VAT breaks on cancer and rare disease drugs until 2027 signals a long-term commitment to supporting healthcare access. This move may incentivize pharmaceutical investments and align with broader health policy objectives, impacting the balance of trade and potentially benefiting companies involved in these sectors.